Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00806754 · ClinicalTrials.gov registry record · Phase 4
Investigation of the Efficacy and Safety of Concomitant Administration of Ciclesonide Nasal Spray and Azelastine Nasal Spray in Patients (18 Years or Older) With Perennial Allergic Rhinitis (PAR) Not Adequately Controlled on an Intranasal Corticosteroid or Antihistamine Monotherapy (BY9010/M1-490)
A Phase 4 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 4
- Development phase
- 340
- Enrollment target
NCT00806754 is a Phase 4 study that has completed, run by AstraZeneca. The registered enrollment target is 340 participants.
The verdict
NCT00806754, a Phase 4 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 340 participants
- Enrollment target
Study Summary
* The primary objective of this study is to evaluate the efficacy of the concomitant administration of ciclesonide nasal spray and azelastine nasal spray versus ciclesonide nasal spray alone in patients (18 years or older) with perennial allergic rhinitis (PAR) not adequately controlled on an intranasal corticosteroid or antihistamine monotherapy * The secondary objective is to investigate the safety of the concomitant administration of ciclesonide nasal spray and azelastine nasal spray
Interventions
- DRUG Ciclesonide nasal spray + placebo Azelastine
- DRUG Ciclesonide nasal spray + Azelastine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 340 participants |
| Start Date | 2006-11 |
| Est. Completion | 2007-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00806754
The ClinicalTrials.gov registry entry for NCT00806754 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 340 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ciclesonide nasal spray + placebo Azelastine is the first listed.
NCT00806754 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00806754 about?
NCT00806754 is a clinical study titled "Investigation of the Efficacy and Safety of Concomitant Administration of Ciclesonide Nasal Spray and Azelastine Nasal Spray in Patients (18 Years or Older) With Perennial Allergic Rhinitis (PAR) Not Adequately Controlled on an Intranasal Corticosteroid or Antihistamine Monotherapy (BY9010/M1-490)". * The primary objective of this study is to evaluate the efficacy of the concomitant administration of ciclesonide nasal spray and azelastine nasal spray versus ciclesonide nasal spray alone in patients (18 years or older) with perennial allergic rhinitis (PAR) not adequately controlled on an intran...
What is the current status of trial NCT00806754?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 340 participants. The study started on 2006-11. Estimated completion is 2007-08.
What interventions are being tested in trial NCT00806754?
The interventions under investigation include: Ciclesonide nasal spray + placebo Azelastine (DRUG), Ciclesonide nasal spray + Azelastine (DRUG).
Who is sponsoring clinical trial NCT00806754?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.